O Mundo Da Saúde · Jul 14, 2026
Senotherapy: scientific advances and clinical potential of senolytic therapies
By Miranda AA, Leal ACM, Fontes AWG et al.
Senotherapy represents an emerging therapeutic approach to combat deleterious senescent cells, whose proinflammatory accumulation contributes to various aging-associated pathologies. This study aimed to analyze and systematize recent scientific advances in senotherapy, with an emphasis on senolytic therapies, their innovations, and clinical potential. An integrative literature review covering the period from January 2019 to June 2025 was conducted in four databases: SciELO, PubMed, ScienceDirect, and Web of Science, following the PRISMA 2020 guidelines for the identification, screening, eligibility, and inclusion stages. A total of 15 articles were selected from 113 publications identified, with predominantly preclinical evidence (13 of the 15 studies were restricted to in vitro or in vivo designs) and only two compounds with reference to preliminary clinical trials. The results demonstrate a rapidly expanding field, with a peak in scientific productivity in 2024, revealing that senolytic therapies predominantly target the modulation of antiapoptotic pathways, such as the Bcl-2 protein family and the PI3K/ AKT/mTOR pathway. Agents such as the combination of dasatinib and quercetin, fisetin, and navitoclax demonstrated preclinical efficacy in models of neurodegenerative diseases, metabolic disorders, musculoskeletal and cardiovascular conditions, as well as in stem cell preservation. However, significant challenges persist, including on-target toxicity (e.g., navitoclax-induced thrombocytopenia), contextual heterogeneity of the response across tissues and age groups, and the absence of validated noninvasive biomarkers in all studies analyzed to quantify senescent burden and monitor therapeutic efficacy. It is concluded that senotherapy is a promising frontier, but its clinical establishment requires coordinated advances in safety, specificity, patient stratification, and standardization to translate preclinical potential into effective applications in aging medicine.
doi.org/10.15343/0104-7809.202650e18732025pOpen accessInterventions